News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TEMIS Complements Leading-Edge Luxid® Semantic Content Enrichment Platform With Best-in-Class Data Analytics and Visualization Capabilities


6/27/2013 9:04:18 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Paris, France & Columbia, MD. – June 27th, 2013 – TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced today that they have acquired the US-based i3 Analytics, a provider of advanced data analytics and visualization technologies, for an undisclosed amount.

Founded in 2011 and employing former NIH (National Institutes of Health) engineers, i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data. Providing customers with tailor-made, relevant and intuitive visualization maps, the i3 Analytics' Biopharma Navigator enables Life Sciences professionals to work faster, provide critical information to their peers, and make fast and informed clinical, regulatory, and business decisions.

Awarded "Best Semantic Technology Solution" in January 2013 by the Software and Information Industry Association (SIIA) for its flagship platform Luxid®, TEMIS has developed an in-depth expertise serving the information extraction and semantic enrichment needs of a varied range of industries, including Defence, Publishing & Media, as well as Life Sciences, where demand for easy-to-use, intuitive visualization and analytics tools has been growing in step with the exponential growth of available unstructured content. This acquisition reinforces TEMIS' commitment and capabilities to serving its customers by strengthening its product range with a complementary SaaS Analytics and Discovery offering and expanding its know-how with the integration of a team of former NIH engineers. The acquisition will also enable TEMIS to accelerate its penetration into new application areas in Life Sciences.

"The acquisition of i3 Analytics demonstrates our commitment to the Life Sciences market", said Eric Brégand, CEO of TEMIS. "This transaction creates a best-in-class offering for our Life Sciences customers, based on the winning combination of deep computational linguistics expertise and leading-edge data visualization know-how. And we will be transposing the solution to other verticals where data analytics and information visualization are also becoming critical."

Moving forward, and with a focus on maintaining its commitment to simplicity and innovation, TEMIS will integrate the SaaS Biopharma Navigator into its Luxid® product line and make it available for other application segments.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
TEMIS
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES